We are live on ! Find out more
PBE icon

Invesco Biotechnology & Genome ETF
PBE

60 hedge funds and large institutions have $55M invested in Invesco Biotechnology & Genome ETF in 2017 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 18 increasing their positions, 13 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 13

4% more capital invested

Capital invested by funds: $52.9M → $55M (+$2.09M)

0.61% less ownership

Funds ownership: 21.64% → 21.02% (-0.61%)

6% less funds holding

Funds holding: 64 → 60 (-4)

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

Holders
60
Holders Change
-4
Holders Change %
-6.25%
% of All Funds
1.5%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
18
Reduced
13
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
IFWM
Institute for Wealth Management
Colorado
+$1.1M
2
RJFSA
Raymond James Financial Services Advisors
Florida
+$311K
3
Morgan Stanley
Morgan Stanley
New York
+$267K
4
Jane Street
Jane Street
New York
+$243K
5
Wells Fargo
Wells Fargo
California
+$225K

Top Sellers

Rank Fund Capital Flow
1
SAM
SignalPoint Asset Management
Missouri
-$3.27M
2
YIA
YHB Investment Advisors
Connecticut
-$213K
3
MML Investors Services
MML Investors Services
Massachusetts
-$208K
4
VF
Virtu Financial
New York
-$89K
5
Creative Planning
Creative Planning
Kansas
-$78K
Name Holding Trade Value Shares
Change 		Change in
Stake
IWM
51
IHT Wealth Management
Illinois
$17K – – –
RFA
52
Reilly Financial Advisors
California
$15K – – –
CAPTRUST Financial Advisors
53
CAPTRUST Financial Advisors
North Carolina
$12K +$11.9K +250 New
PNC Financial Services Group
54
PNC Financial Services Group
Pennsylvania
$11K – – –
AIM
55
Advantage Investment Management
Iowa
$10K – – –
WAM
56
Wealthspire Advisors (Maryland)
Maryland
$5K – – –
ASN
57
Advisory Services Network
Georgia
$4K -$3.89K -82 -53%
JP Morgan Chase
58
JP Morgan Chase
New York
$4K – – –
AIP
59
Ameritas Investment Partners
Nebraska
$2K – – –
Creative Planning
60
Creative Planning
Kansas
– -$78K -1,700 Closed
AP
61
Advisors Preferred
Maryland
– -$15K -331 Closed
AA
62
AlphaMark Advisors
Kentucky
– -$8K -180 Closed
DADC
63
D.A. Davidson & Co
Montana
– -$4K -100 Closed
WEC
64
Winslow Evans & Crocker
Massachusetts
– -$2.28K -50 Closed
VWA
65
V Wealth Advisors
Kansas
– -$2K -35 Closed
1 2
3

PBE Hedge Fund Activity: Q3 2017 in Review

60 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q3 2017, worth a combined $55M — up 3.9% from $52.9M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of PBE and 4 opened new positions — a net loss of 2 holders — while 13 trimmed existing stakes and 18 added.

The largest buyer was Institute for Wealth Management, opening a new position worth an estimated $1.1M. The largest seller was SignalPoint Asset Management, cutting an estimated $3.27M.

  • 60 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q3 2017, down from 64 in Q2 2017.
  • Funds reported $55M of Invesco Biotechnology & Genome ETF stock for Q3 2017, up 3.9% quarter-over-quarter.
  • 4 funds opened new Invesco Biotechnology & Genome ETF positions in Q3 2017 and 6 closed out, a net change of -2 holders.
  • The largest Invesco Biotechnology & Genome ETF buyer in Q3 2017 was Institute for Wealth Management, an estimated $1.1M added.
  • The largest Invesco Biotechnology & Genome ETF seller in Q3 2017 was SignalPoint Asset Management, an estimated $3.27M sold.

Based on aggregated 13F filings for Q3 2017.